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OBJECTIVES: To compare Computed Tomographic (CT) utilization and poten-
tially related cancer risks in the United States and in Canada. METHODS: While 
CT scans can provide great medical benefits, there is growing concern about 
potential cancer risks because they deliver much higher radiation doses than do 
conventional diagnostic x-rays. Using epidemiological databases, we developed a 
risk projection model to assess radiation exposure from CT use, to estimate the 
number of CT related incident cancers, according to age, gender, and CT scan 
type in Canada. 95% uncertainty limits (UL) using Monte Carlo simulations were 
estimated. These results were compared to projected cancer risks from CT scans 
performed in the United States. RESULTS: In 2007, there were 240,000 and 
114,000 CT examinations per million population in the United States and 
Canada, respectively. Scans of the abdomen/pelvis, brain, and thorax accounted 
for 88% and 78% of all CT scans in Canada and the United States. We estimated 
46 (95% UL 24 - 89) potential CT-related incident cancers per million in Canada, 
compared to 98 (51 - 152) in the United States. In the United States, 48% of 
potential cancers might be attributed to abdomen/pelvis CT scans, while in 
Canada the estimate is 66%. In Canada, 36 (18 - 71) and 56 (29 - 106) potential 
cancers per million were estimated for males and females, respectively. In the 
United States, the estimates were 76 (41 -110) and 119 (60 - 185) per million for 
males and females, respectively. CONCLUSIONS: Given the different patterns of 
care in the United States and in Canada, our findings might have important 
health policy implications. Strategies to monitor the appropriate use of CT scans, 
especially CT abdomen/pelvis, should be followed. Efforts to reduce cancer risk 
might include decreasing the number of decisionally marginal CT scans, as well 
as the dose per scan.  
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OBJECTIVES: To assess the impact of not screening for prostate cancer among a 
hypothetical population of men >55 years of age. METHODS: Sample included 
PLCO Screening Trial intervention participants without cancer at T0 (n=33,709) 
through 2011. Inclusion criteria: age ≥55 years, and adequate PSA or DRE exam at 
entry. Cancer was considered clinically significant if patient had confirmed PCa 
with Gleason score ≥7. Estimated PCa expenditures were based on Medicare 
costs. Results were projected to SEER incident population (n=202,500 with 
localized cancer). RESULTS: Among 2,580 PLCO men identified and treated for 
PCa after T0, estimated total expenditures were: $61.5 million, with $23,804 per 
treated patient. Among 377 PLCO men with clinically significant cancers who 
received treatment, estimated total expenditures were $8.6 million (mean, 
$22,742 per patient). Among 549 PLCO men with clinically non-significant PCa 
identified and treated after T0, estimated total expenditures were $13.6 million 
($24,831 per case). Extrapolated nationally to 96,000 clinically significant PCas 
annually, annual initial diagnosis/ treatment costs would be $2.4 billion. 
Adopting draft USPHSTF recommendations would result in $2.4 billion in initial 
savings ($23,804/patient). Many of these men will subsequently present with 
clinically significant PCa, will require systemic therapy, and will die from PCa, 
with total costs far exceeding $2.4 billion. CONCLUSIONS: The 2011 USPHSTF 
Task Force draft policy currently grades PCa screening as “(D)- do not discuss 
with patients.” A more rational policy would be to screen appropriate men for 
PCa and to treat early clinically significant PCa with surgery or radiation.  
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OBJECTIVES: We sought to describe the new molecular entities (NMEs) and new 
therapeutic biologic applications (BLAs) approved by the US Food and Drug 
Administration (FDA) in the period 1980-2012, and to assess differences in drug 
approvals and discontinuations between oncology products and products from 
other therapeutic classes. METHODS: Drug approval data were collected from 
FDA databases publicly available on its website, and the FDA Approved Drug 
Products with Therapeutic Equivalence Evaluations (1980-2012). The unit of 
analysis was the pharmaceutical active ingredient or combination of ingredients 
approved by the FDA. Data were updated to December 31, 2012. Descriptive 
analysis and the chi-square test were used in the analysis. RESULTS: The FDA 
listed 2,479 approved active ingredients or combinations of active ingredients in 
the period 1980-2012; including 99 BLAs and 2,380 NMEs. Oncology products 
represented 5.3% (n=126) of NMEs and 43.4% (n=43) of BLAs. The FDA listed 34 
oncology products approved before 1980, 12 in the 1980s, 49 in the 1990s, 51 in 
the 2000s, and 23 in 2010-2012. The oncology products (0.6%) and other products 
(23.8%) were approved as a fixed-dose combination (p<0.001). In January 1, 1980 
the FDA listed 949 products of which 33 (3.5%) were oncology products. In the 
period 1980-2012, the FDA approved 1,530 products, including 136 oncology 
products (8.9%). In December 31, 2013, 92.9% of all the approved oncology 
products and 68.7% of other products were listed as marketed by the FDA 
(p<0.001). CONCLUSIONS: Oncology drugs experienced a rapid increase in 
approvals in the past 2 decades while the approvals in other therapeutic classes 
declined significantly. Biologics represented a larger proportion of the approvals 
of oncology products than products from other therapeutic classes. 
Pharmaceutical companies continue to invest in R&D in oncology and other 
niche markets without adequate therapeutic alternatives.  
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OBJECTIVES: Lung cancer is the most frequent cause of cancer death with 
cigarette smoking being the number one risk factor. Nearly 90% of lung cancer 
deaths are attributable to smoking. Smoking in patients diagnosed with lung 
cancer decreases the rate of survival, quality of life, and reduces the 
effectiveness of medical treatment in these patients. One of the ways to stop 
smoking is through the use of smoking cessation agents. The purpose of this 
study is to explore the prevalence of smoking among lung cancer patients and 
patient reported use of smoking cessation agents using a national dataset. 
METHODS: A retrospective study was done to identify lung cancer patients (ICD-
9 = 162) who smoke and those who use smoking cessation agents from 2006-2010 
using Medical Expenditure Panel Survey (MEPS) data. Number of patients who 
smoke and those who use smoking cessation agents were described. RESULTS: 
Data from five years identified nearly 260 lung cancer patients. Out of these, 48 
patients, accounting for 18.4% prevalence, reported smoking even after 
diagnosed with lung cancer. Percentage of female smokers was 58.33% while that 
of males was 41.66%. Medication history for these patients revealed a very low 
proportion, (i.e. 6/48 or 12.5%) reported using any form of smoking cessation 
agents. CONCLUSIONS: It is evident from the results that significant numbers of 
patients continue smoking even after diagnosis. This might be an 
underestimated number as this was patient reported information. There may be 
more patients that have not reported smoking because of social dogma. This 
shows that the non-medical efforts to quit smoking might have been 
unsuccessful. Also, the use of smoking cessation agents among these patients is 
extremely low. This is an alarming matter and future research should focus on 
identifying barriers to use of smoking cessation agents and approaches to 
address those barriers.  
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OBJECTIVES: Bevacizumab (Bev, Avastin®), the first FDA-approved anti-
angiogenesis agent, has been used as adjuvant therapy for the treatment of 
metastatic colorectal cancer (mCRC) since 2004. This study aimed to evaluate the 
utilization of Bev among elderly mCRC patients aged 65 and older within the US. 
METHODS: This retrospective cohort study used the SEER-Medicare data. Our 
cohort included individuals aged 65 years or older who were incident CRC 
patients diagnosed in 2005-2007 and received chemotherapy at any time through 
December 2009 (date of first chemotherapy = index date). This included patients 
with newly diagnosed metastatic disease, as well as CRC patients who 
progressed from initially diagnosed localized/regional disease (recurrence). We 
ascertained comorbid conditions using ICD-9 codes from inpatient, outpatient, 
and physician claims within one year prior to the index date. Logistic regression 
adjusted for patient characteristics was conducted to assess the likelihood of Bev 
use. RESULTS: A total of 6,804 patients were identified. The mean age at index 
date was 74 years and 50.3% were male. There were 2,792 (41.0%) patients 
received Bev, among which the average number of Bev cycles was 11.9 
(median=9). Bev was used in 64% of patients with metastatic CRC and 26% of 
patient with recurrent disease. After adjustment for all other variables, we found 
that patients were less likely to receive Bev if they were with age>=80 compared 
with those aged 65-69 (adjusted odds ratio [OR] = 0.81 [95% CI: 0.69-0.94]; p<0.01), 
or had evidence of arterial thromboembolism (OR = 0.70 [0.54-0.90; p<0.0001) 
prior to chemo initiation. We also observed a trend of increasing Bev use over 
calendar time as well as substantial geographic variation in its use. 
CONCLUSIONS: Less than half of Bev-indicated patients received Bev in US 
Medicare population. Patients’ age and history of arterial thromboembolism 
significantly contribute to the low utilization of Bev.  
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OBJECTIVES: To analyzed the pattern and factors associate with the utilization 
of Traditional Chinese Herbal Medicine (TCHM) in Traditional Chinese Medicine 
(TCM) hospitals in China. METHODS: We examined 87,248 inpatient records in 
100 TCM hospitals from 2003 to 2007. Use of TCHM are analysed by a logit model. 
Major factors associate with the utilization includes patients’ and hospitals’ 
characteristics. RESULTS: TCHM use is positively related to a patient’s age. 
Female, ethnic group, health insurance status, and disease types also associate 
with TCHM utilization. Patients in critical conditions (OR=1.27, P<0.01) are more 
likely to use TCHM than those in stable conditions. However, patients admitted 
from emergency department are less likely to use TCHM (OR=0.75, P<0.01). 
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Patients from higher rank hospitals received more TCHM treatment (OR=1.12, 
P<0.01) than their counter parts. Use of TCHM is also higher (OR=2.49, P<0.01) in 
eastern(developed area) than in mid-western(developing area). CONCLUSIONS: 
 F Factors associate with utilization of TCHM include both patient demand and 
TCHM service supply. The study calls for further investigations on availability of 
TCHM and practitioners in different geographic locations. It is also worthwhile to 
identify comparative advantages of TCHM to western medicine in treating 
different conditions in order to fulfill its roles with the current Chinese health 
care reform.  
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OBJECTIVES: China’s evolving health care market demands advanced oncology 
agents for its patients; however, the formulary (drug list) access system for these 
drugs is complex to navigate. This research aims to identify those critical factors 
that support formulary access and utilization for “advanced oncology agents 
(AOA)” in China. METHODS: Telephonic interviews were conducted with twelve 
formulary decision makers and influencers (FDM) from three large provinces in 
China, Beijing, Shanghai, and Guangzhou. FDM were identified and selected for 
their role in access and reimbursement decisions in their local health care 
systems, and included pharmacoeconomists, insurance officers, directors of 
hospital pharmacy, and key opinion leading oncologists (KOL). Each FDM was 
interviewed in their native language for 60 to 90 minutes. Responses were 
tabulated and analyzed. RESULTS: Interviews revealed that none of the AOA are 
covered in the National Reimbursement Drug List (NRDL), however, some are 
reimbursed at the provincial level on the Provincial Reimbursement Drug List 
(PRDL). The provinces that include AOA on their PRDL share common attributes, 
most notably, the local government has significant decision-making power, and 
its medical insurance fund has a relatively high balance. Factors that influence 
AOA utilization in China include physician willingness to prescribe, support by 
regional KOL, patient affordability, listing on hospital and provincial drug lists, 
and hospital budget. There are locally-funded insurance programs, and 
manufacturer-funded patient-assistance programs, available to help reduce the 
patient-burden of treatment for chronic and high-cost diseases. KOL are critical 
to the decisions to include AOA in these programs. CONCLUSIONS: The critical 
success factors that support access and utilization of AOA in China include 
advocacy for drug listing by regional KOL, achieving listing on local hospital drug 
lists, and inclusion of drugs in local insurance- and manufacturer-funded patient 
programs.  
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OBJECTIVES: Melanoma is a skin cancer originated in melanocytes and is 
predominant in white adults. Skin cancer is the most common cancer in Brazil 
corresponding to 25% of all malignant tumors registered. Melanoma accounts for 
only 4% of the malignant neoplasms of the skin, but it has very high lethality. 
The objective of this research is to describe resource utilization and costs 
associated with melanoma treatment in Brazil and across the country’s regions; 
to compare chemotherapy and surgery in relation to patients’ characteristics and 
average costs. METHODS: A sample of 3 million Brazilian supplementary health 
care system patients was accessed in a electronic administrative database 
(BI.2iM) to identify resource utilization in 2011. The search was retrospective and 
conducted using the melanoma ICD 10 code (C43) as driver. Cost information is 
in Brazilian reais (US$1.00 = R$ 2.00) RESULTS: 94 patients were identified by the 
melanoma IC10 code in 2011. These patients sample consumed R$ 9,1 million 
(mean annual cost of R$ 96,268) with 81% of these costs referred to surgical 
procedures, radiotherapy 12%, chemotherapy 1% and others expendures 6%. 
Projecting the number of cases found in BI.2iM in the population covered by 
health plans in Brazil it would be expected around 1,504 cases to be treated per 
year at a potential cost of 144, 7 million. CONCLUSIONS: This data suggest that 
surgical procedures are the main cost related with the melanoma treatment in 
the Brazilian supplementary health care system. Understanding treatment 
preferences and patterns is mandatory to analyze new treatments cost-
effectiveness ratio.  
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OBJECTIVES: With the approval of imatinib (ima), systemic therapy (ST) for 
gastrointestinal stromal tumors (GIST) has changed substantially. This study 
evaluated treatment patterns and costs of patients receiving first-line (1LT) ima 
for GIST. METHODS: A retrospective study spanning 1/1/03-9/30/11 was 
conducted utilizing pharmacy/medical claims data from a large health plan. 
Patients with GIST-related ICD9 codes who initiated ima were eligible. Patients 
were excluded if they received any chemotherapy prior to date of first diagnosis 
or ima. Adjuvant patients (APs) were defined as receiving GIST-related surgery 
prior to ima. Patients were followed from diagnosis to end of the study period or 
loss of continuous eligibility to describe post-ima ST and evaluate corresponding 
GIST-related average monthly costs. RESULTS: One hundred patients (45 APs) 
with average follow-up time of 1113 days (range 385–2,901 days) met all inclusion 
criteria. The average time between first diagnosis and initiation of ima therapy 
was 207 days for AP versus 140 days for non-adjuvant patients (NAPs). Average 
monthly costs prior to ima therapy were $7,025; APs, $11,095/month. APs 
remained on ima therapy for an average of 463 days versus 404 days for NAPs. 
Monthly therapy costs across both cohorts were $3919 (SD=$1822), almost 92% of 
total monthly costs. Twenty-one patients moved onto post-ima second-line 
therapy (2LT), with 81% (n=17) receiving sunitinib (sun). APs moving onto 
second-line therapy remained on treatment 148 days versus 256 days for NAPs. 
2LT average monthly cost: AP=$8813; NAP=$5894; over 70% related to ST. 6 of the 
21 patients received third-line therapy (3LT) (3-nilotinib, 2-sorafenib, 1-
cyclophosphamide) for an average of 48 days; treatment costs averaged 
$1774/month. CONCLUSIONS: Post-ima 2LT for GIST was dominated by sun, 
while 3LT varied among the few patients who initiated this line of care. Across 
all lines of care, therapy cost was the primary driver of cost.  
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OBJECTIVES: To investigate the effect of Medicare’s cut in chemotherapy 
reimbursement (implemented in 2004-2005) on rituximab prescription among 
Non-Hodgkin’s Lymphoma (NHL) patients and to estimate the marginal survival 
benefits of rituximab using an instrumental variable (IV) approach. METHODS: 
Using the Surveillance, Epidemiology and End Results (SEER)-Medicare linked 
database, we studied patients 66 years or older diagnosed with first primary NHL 
from 2002-2007 (N=19,424). Logistic regression was used to assess the impact of 
Medicare reimbursement cut on first course rituximab prescription, after 
controlling for clinical and non-clinical factors. Two stage least square 
regressions using Medicare reimbursement policy as IV were used to estimate 
whether the changes in the rituximab prescription rates could lead to one and 
three years of survival benefit. RESULTS: In the post-policy period (2004-2008) 
the likelihood of rituximab prescriptions increased as compared to the pre-policy 
period (AOR of 1.52 in 2004, AOR of 1.79 in 2005 and after, respectively). Using IV 
approach, we found that the first course of rituximab prescription among NHL 
patients significantly improved one- and three-year survival (effectiveness 
estimate=0.37 for one-year survival, effectiveness estimate=0.44 for three-year 
survival respectively). CONCLUSIONS: Rituximab prescriptions increased in 
response to the Medicare’s reimbursement cut. Substantial rituximab survival 
benefits were observed among marginal NHL patients whose treatment choices 
were affected by the policy change.  
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OBJECTIVES: The Medicare Prescription Drug, Improvement and Modernization 
Act of 2003 (MMA) changed reimbursement of outpatient drugs reimbursed 
under Medicare Part B from 95% of average wholesale price to 106% of the 
average sales price as a cost saving measure. Shortly thereafter many 
commercial payers followed suit. This analysis examines the impact of the 
change in the reimbursement schedules on actual payments provided to 
physicians for administrations of 5 high cost Part B reimbursed oncology drugs. 
METHODS: Using the MarketScan Research Databases©, claims for 
administrations of pemetrexed, bevacizumab, trastuzumab, rituximab, 
docetaxel, and zoledronic acid were identified from January 1, 2004 through 
December 31, 2011 among cancer patients with non-capitated commercial or 
employer-sponsored supplemental Medicare insurance. Claims were excluded 
from the payment analysis if the reimbursed amount was less than $100 to omit 
use for other indications, such as the use of bevacizumab for treatment of 
macular degeneration. Median reimbursed amounts, encompassing both plan 
and patient paid amounts, were reported by year, after adjusting to 2011 dollars 
using the consumer price index. Compound annual growth rates (CAGRs) 
between 2004 and 2011 were computed to assess the change in reimbursements 
over time. RESULTS: A total of 1.98M Commercial and 839k Medicare claims were 
analyzed. Negative CAGRs between 2004-2011 were observed in only two of the 
therapies: pemetrexed (-11% CAGR in Commercial population) and zoledronic 
acid (-2 % to -3% in the Medicare and Commercial population, respectively). The 
remaining oncology Part B therapies exhibited CAGRs of 1-5%, with the exception 
of trastuzumab which had 11-13% growth. CONCLUSIONS: The amount 
reimbursed for several key oncology therapies administered in providers offices 
did not shift dramatically downward after the implementation of MMA. Further 
research will examine shifts in dosage levels, frequency, and location of 
administrations (office vs. hospital) to determine the drivers of the upward shift 
in average reimbursed amount per claim.  
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